NantHealth Inc (NYSE:NH)‘s stock had its “buy” rating reiterated by equities researchers at Canaccord Genuity in a research report issued on Monday. They currently have a $17.00 target price on the stock. Canaccord Genuity’s price target suggests a potential upside of 28.69% from the company’s current price.

Several other research firms have also recently issued reports on NH. Zacks Investment Research cut NantHealth from a “hold” rating to a “sell” rating in a research note on Wednesday, August 31st. Cowen and Company assumed coverage on NantHealth in a research note on Monday, June 27th. They issued an “outperform” rating and a $19.00 target price on the stock. FBR & Co assumed coverage on NantHealth in a research note on Monday, June 27th. They issued an “outperform” rating and a $18.00 target price on the stock. First Analysis assumed coverage on NantHealth in a research note on Monday, June 27th. They issued an “overweight” rating and a $18.00 target price on the stock. Finally, Jefferies Group assumed coverage on NantHealth in a research note on Monday, June 27th. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $18.00.

Shares of NantHealth (NYSE:NH) opened at 13.21 on Monday. The company’s market capitalization is $1.60 billion. The firm’s 50-day moving average price is $12.22 and its 200-day moving average price is $12.57. NantHealth has a one year low of $9.79 and a one year high of $16.63.

NantHealth (NYSE:NH) last posted its earnings results on Tuesday, August 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.26. The business earned $31.50 million during the quarter, compared to the consensus estimate of $23.55 million. NantHealth’s revenue was up 166.9% compared to the same quarter last year. Analysts anticipate that NantHealth will post ($0.55) earnings per share for the current year.

A number of hedge funds have recently modified their holdings of NH. Blackstone Group L.P. bought a new stake in shares of NantHealth during the second quarter valued at approximately $7,463,000. Jefferies Group LLC bought a new stake in shares of NantHealth during the second quarter valued at approximately $6,943,000. Wildcat Capital Management LLC bought a new stake in shares of NantHealth during the second quarter valued at approximately $3,008,000. Finally, FMR LLC bought a new stake in shares of NantHealth during the second quarter valued at approximately $11,250,000.

NantHealth Company Profile

NantHealth, Inc, formerly Nant Health, LLC, is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

5 Day Chart for NYSE:NH

Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.